Host-response testing with MeMed BV in community-acquired pneumonia: an economic evaluation from the UK NHS perspective.

ABSTRACT:

Background

Community-acquired pneumonia (CAP) remains a leading cause of hospital admissions and mortality. A novel host-response test, MeMed BV (MMBV), has been developed for discriminating between bacterial and viral infection that could improve the clinical management of CAP.

Objectives

To evaluate the cost-effectiveness of using MMBV to guide antibiotic decisions in the clinical management of CAP in the UK.

Methods

An economic model was developed to understand the incremental cost per person associated with the implementation of MMBV from the UK NHS perspective. A qualitative care pathway analysis was performed to inform the standard of care (SOC) and SOC plus MMBV (SOC + MMBV) clinical pathways captured in the model.

Results

In the base case analysis, the

SUBMITTER: Gregg E 

PROVIDER: S-EPMC11836884 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature